Get started
Author

Frances Anne Tosto

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024 · Christopher Melani, Rahul Lakhotia, et al. · New England Journal of Medicine · 75
PDF
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma
2021 · Anne C. Wilke, Carmen Doebele, et al. · Blood · 46
PDF
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
2022 · Yandan Yang, Arnold Bolomsky, et al. · Nature Communications · 29
PDF
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma
2023 · Nadia Arang, Simone Lubrano, et al. · Cell Reports Medicine · 25
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
2020 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 17
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity
2024 · Michele Ceribelli, Frances Anne Tosto, et al. · Proceedings of the National Academy of Sciences · 9
PDF
Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2023 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 6
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
2022 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 6
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
2024 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 4
PDF
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2022 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 3
45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)
2025 · C. Melani, R. Lakhotia, et al. · Hematological Oncology · 2
PDF
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma
2022 · Yandan Yang, Arnold Bolomsky, et al. · Nature Communications · 2
PDF
316 | Multi‐targeted Therapy With Vipor‐p in Relapsed/refractory Diffuse Large B‐cell Lymphoma: Updated Analysis of Efficacy and Minimal Residual Disease
2025 · C. Melani, R. Lakhotia, et al. · Hematological Oncology · 1
PDF
Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
2024 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 1
POSTER: MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
2023 · Rahul Lakhotia, Stefania Pittaluga, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)
2023 · C. J. Melani, R. Lakhotia, et al. · Hematological Oncology · 1
PDF
Abstract A027: Combination targeted therapy with ViPOR in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL): Analysis of safety, efficacy, and minimal residual disease (MRD)
2026 · Christopher Melani, Rahul Lakhotia, et al. · Blood Cancer Discovery
MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
2023 · Rahul Lakhotia, Stefania Pittaluga, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract B06: Development of selective LATS1/LATS2 inhibitors for the pharmacologic modulation of the Hippo signaling pathway
2020 · Michele Ceribelli, Patrick Morris, et al. · Molecular Cancer Research
Works count: 19
Citation count: 228
H-index: 6
I10-index: 5
Year
Topic
Type